General Information of the Compound
| Compound ID |
CP0528362
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
(S)-3-{(1S,3S)-3-[4-(2-Cyano-phenyl)-piperidin-1-yl]-cyclopentylcarbamoyl}-4-(3,4-difluoro-phenyl)-6-methoxymethyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid methyl ester
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C32H35F2N5O5
|
||||||||||||||||||
| Molecular Weight |
607.658
|
||||||||||||||||||
| Canonical SMILES |
COCC1=C([C@@H](N(C(=O)N[C@H]2CC[C@@H](C2)N2CCC(CC2)c2ccccc2C#N)C(=O)N1)c1ccc(F)c(F)c1)C(=O)OC
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C32H35F2N5O5/c1-43-18-27-28(30(40)44-2)29(20-7-10-25(33)26(34)15-20)39(32(42)37-27)31(41)36-22-8-9-23(16-22)38-13-11-19(12-14-38)24-6-4-3-5-21(24)17-35/h3-7,10,15,19,22-23,29H,8-9,11-14,16,18H2,1-2H3,(H,36,41)(H,37,42)/t22-,23-,29-/m0/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
JWAHBXONODWUEH-BOSRLCDASA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01089, Alpha-1A adrenergic receptor
Protein ID: PT01007, Alpha-1B adrenergic receptor
Protein ID: PT01004, Alpha-1D adrenergic receptor